EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Synthesis, docking study, and antitumor evaluation of benzamides and oxadiazole derivatives of 3‐phenoxybenzoic acid as VEGFR‐2 inhibitors

Mohammad H Heriz, Ammar A R Mahmood, Salem R Yasin, Khaled M Saleh iD, Mai F AlSakhen, Sana I Kanaan, Nisreen Himsawi, Abdulrahman M Saleh, Lubna H Tahtamouni iD

Drug Development Research · 2024

DOI: 10.1002/ddr.22186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2024. Verfasst von Mohammad H Heriz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq. Hauptthemen laut MEDLINE: Benzamides, Antineoplastic Agents, Benzoates. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Deanship of Scientific Research, The Hashemite University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current chemotherapeutic agents have several limitations, including lack of selectivity, the development of undesirable side effects, and chemoresistance. As a result, there is an unmet need for the development of novel small molecules with minimal side effects and the ability to specifically target tumor cells. A new series of 3‐phenoxybenzoic acid derivatives, including 1,3,4‐oxadiazole derivatives ( 4a–d ) and benzamides derivatives ( 5a–e ) were synthesized; their chemical structures were confirmed by Fourier‐transform infrared spectroscopy, 1 H nuclear magnetic resonance (NMR), 13 C NMR, and mass spectra; and various physicochemical properties were determined. The antiproliferative activities of the new derivatives were evaluated by means of the 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay. Three compounds ( 4b , 4c , and 4d ) exhibited cytotoxicity against two of the three cell lines tested, five compounds ( 3 , 4a , 5a , 5b , and 5e ) were toxic to one cell line, while two compounds ( 5c and 5d ) were not cytotoxic to any of the three cell lines tested in the current study. Based on docking scores, MTT assay findings, and vascular endothelial growth factor receptor 2 (VEGFR‐2) kinase activity data, Compound 4d was selected for further biological investigation. Flow cytometry was used to determine the mode of cell death (apoptosis vs. necrosis) and the effect on cell cycle progression. Compound 4d arrested HepG2 hepatocellular carcinoma cells in the G2/M phase and activated both the intrinsic and extrinsic apoptosis pathways. In conclusion, Compound 4d has shown promising results for future research as a potent VEGFR‐2 tyrosine kinase inhibitor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzamidesAntineoplastic AgentsBenzoatesMolecular StructureStructure-Activity RelationshipVascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor ACell ProliferationProtein Kinase InhibitorsMolecular Docking SimulationDrug Screening Assays, AntitumorCell Line, TumorDrug Design

Stichwörter der Autor:innen

1,3,4‐oxadiazole3‐phenoxybenzoic acidVEGFR‐2 inhibitorsapoptosisbenzamide

Substanzen

3-phenoxybenzoic acidBenzamidesVascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor AAntineoplastic AgentsProtein Kinase InhibitorsBenzoates

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq.
  • Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
  • Department of Microbiology, Pathology and Forensic Medicine, Faculty of Medicine, The Hashemite University, Zarqa, Jordan.
  • Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
  • Epidemiological Surveillance Unit, Aweash El-Hagar Family Medicine Center, MOHP, Mansoura, Egypt.

ORCID-Profile: Khaled M Saleh, Lubna H Tahtamouni

Förderung

  • The Deanship of Scientific Research, The Hashemite University

Zitieren

APA

Heriz, M. H., Mahmood, A. A. R., Yasin, S. R., Saleh, K. M., AlSakhen, M. F., Kanaan, S. I., Himsawi, N., Saleh, A. M., & Tahtamouni, L. H. (2024). Synthesis, docking study, and antitumor evaluation of benzamides and oxadiazole derivatives of 3‐phenoxybenzoic acid as VEGFR‐2 inhibitors. Drug Development Research. https://doi.org/10.1002/ddr.22186

Vancouver

Heriz MH, Mahmood AAR, Yasin SR, Saleh KM, AlSakhen MF, Kanaan SI, et al. Synthesis, docking study, and antitumor evaluation of benzamides and oxadiazole derivatives of 3‐phenoxybenzoic acid as VEGFR‐2 inhibitors. Drug Development Research. 2024. doi:10.1002/ddr.22186

BibTeX
@article{Heriz2024,
  author = {Heriz, Mohammad H and Mahmood, Ammar A R and Yasin, Salem R and Saleh, Khaled M and AlSakhen, Mai F and Kanaan, Sana I and Himsawi, Nisreen and Saleh, Abdulrahman M and Tahtamouni, Lubna H},
  title = {Synthesis, docking study, and antitumor evaluation of benzamides and oxadiazole derivatives of 3‐phenoxybenzoic acid as VEGFR‐2 inhibitors},
  journal = {Drug Development Research},
  year = {2024},
  doi = {10.1002/ddr.22186}
}
Kostenlos starten →